IL276910B2 - Total afucosylated glycoforms of antibodies produced in cell culture - Google Patents

Total afucosylated glycoforms of antibodies produced in cell culture

Info

Publication number
IL276910B2
IL276910B2 IL276910A IL27691020A IL276910B2 IL 276910 B2 IL276910 B2 IL 276910B2 IL 276910 A IL276910 A IL 276910A IL 27691020 A IL27691020 A IL 27691020A IL 276910 B2 IL276910 B2 IL 276910B2
Authority
IL
Israel
Prior art keywords
cell culture
culture medium
fucose
concentration
level
Prior art date
Application number
IL276910A
Other languages
English (en)
Hebrew (he)
Other versions
IL276910A (en
IL276910B1 (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL276910A publication Critical patent/IL276910A/en
Publication of IL276910B1 publication Critical patent/IL276910B1/en
Publication of IL276910B2 publication Critical patent/IL276910B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL276910A 2018-03-26 2019-03-26 Total afucosylated glycoforms of antibodies produced in cell culture IL276910B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648308P 2018-03-26 2018-03-26
PCT/US2019/024154 WO2019191150A1 (en) 2018-03-26 2019-03-26 Total afucosylated glycoforms of antibodies produced in cell culture

Publications (3)

Publication Number Publication Date
IL276910A IL276910A (en) 2020-10-29
IL276910B1 IL276910B1 (en) 2024-08-01
IL276910B2 true IL276910B2 (en) 2025-11-01

Family

ID=66102281

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276910A IL276910B2 (en) 2018-03-26 2019-03-26 Total afucosylated glycoforms of antibodies produced in cell culture
IL313983A IL313983A (en) 2018-03-26 2019-03-26 Fully fucose-free glycoforms of antibodies are produced in cell culture

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL313983A IL313983A (en) 2018-03-26 2019-03-26 Fully fucose-free glycoforms of antibodies are produced in cell culture

Country Status (15)

Country Link
US (2) US12325737B2 (https=)
EP (1) EP3775251A1 (https=)
JP (2) JP2021519068A (https=)
KR (2) KR20200135781A (https=)
CN (2) CN111954719B (https=)
AU (2) AU2019243848B2 (https=)
BR (1) BR112020019559A2 (https=)
CA (1) CA3093853A1 (https=)
CL (1) CL2020002450A1 (https=)
EA (1) EA202092286A1 (https=)
IL (2) IL276910B2 (https=)
MA (1) MA52186A (https=)
MX (2) MX2020009907A (https=)
SG (1) SG11202009216YA (https=)
WO (1) WO2019191150A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
WO2021122738A1 (en) * 2019-12-19 2021-06-24 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113960232B (zh) * 2021-10-28 2024-02-20 苏州大学 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用
AU2024256160A1 (en) * 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120347A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017134667A1 (en) * 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Methods of generating antibodies

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2315251A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
IL136696A0 (en) 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CA2318030C (en) 1998-01-23 2009-02-17 Immunex Corporation Acpl dna and polypeptides
EP1108042B1 (en) 1998-08-07 2008-11-26 Immunex Corporation Molecules designated b7l-1
AU776825B2 (en) 1998-08-07 2004-09-23 Immunex Corporation Molecules designated LDCAM
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
CA2421588C (en) 2000-09-05 2010-01-26 Amgen Inc. Tnf receptor-like molecules and uses thereof
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2003024389A2 (en) 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
WO2003048327A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
DE60226499D1 (de) 2001-12-28 2008-06-19 Amgen Fremont Inc Verwendung von antikörpern gegen das muc18-antigen
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
NZ542784A (en) 2002-08-19 2008-07-31 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
AR045056A1 (es) 2003-07-15 2005-10-12 Amgen Inc Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
CA2561823A1 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies of angiogenesis inhibiting domains of cd148
AU2005250341A1 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of CD148
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
EP2397498A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
NZ566774A (en) 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
DK1979001T3 (da) 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
MX2008014710A (es) 2006-05-19 2009-02-12 Amgen Inc Anticuerpos para coronavirus del sars.
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
JP2010532158A (ja) 2007-04-02 2010-10-07 アムジェン フレモント インク． 抗ＩｇＥ抗体
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011127322A1 (en) 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114167A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
US9283371B2 (en) 2012-02-29 2016-03-15 Thu-Ha Duncan Electro-stimulation system
CN103320388B (zh) * 2012-03-20 2015-10-28 无锡药明康德生物技术股份有限公司 提高抗体表达量和改良糖基化水平的细胞培养方法
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
NO2760138T3 (https=) 2012-10-01 2018-08-04
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
SG11201600067YA (en) 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
WO2015128793A1 (en) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited A process for modifying high mannose and galactosylation content of a glycoprotein composition
BR112016017660B1 (pt) 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
US10544395B2 (en) 2014-03-19 2020-01-28 Pfizer Inc. Method of cell culture
US20160115225A1 (en) 2014-10-24 2016-04-28 Abbvie Inc. Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture
CA2969225C (en) * 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
ES2875274T3 (es) * 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
WO2017081093A1 (en) * 2015-11-11 2017-05-18 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins
CA3010600A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120347A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017134667A1 (en) * 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Methods of generating antibodies

Also Published As

Publication number Publication date
MX2025015600A (es) 2026-02-03
AU2024278151A1 (en) 2025-01-02
CL2020002450A1 (es) 2020-12-28
MA52186A (fr) 2021-02-17
IL276910A (en) 2020-10-29
BR112020019559A2 (pt) 2021-01-12
US20250197479A1 (en) 2025-06-19
IL313983A (en) 2024-08-01
US20210079065A1 (en) 2021-03-18
JP2024019717A (ja) 2024-02-09
CN111954719A (zh) 2020-11-17
EA202092286A1 (ru) 2021-03-18
CA3093853A1 (en) 2019-10-03
EP3775251A1 (en) 2021-02-17
AU2019243848B2 (en) 2025-01-02
US12325737B2 (en) 2025-06-10
JP2021519068A (ja) 2021-08-10
KR20200135781A (ko) 2020-12-03
KR20260011202A (ko) 2026-01-22
WO2019191150A1 (en) 2019-10-03
CN111954719B (zh) 2025-07-18
MX2020009907A (es) 2020-10-14
IL276910B1 (en) 2024-08-01
AU2019243848A1 (en) 2020-09-17
SG11202009216YA (en) 2020-10-29
CN119639849A (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
US20250197479A1 (en) Total afucosylated glycoforms of antibodies produced in cell culture
US20260103716A1 (en) Control of total afucosylated glycoforms of antibodies produced in cell culture
JP2026009152A (ja) 抗体組成物を製造する方法
JP2023548767A (ja) 抗体製造方法における相対不対グリカン
US20240279704A1 (en) Using fucosidase to control afucosylation level of glycosylated proteins
EA045782B1 (ru) Общие афукозилированные гликоформы антител, полученные в культуре клеток
US20250076309A1 (en) Fc-gamma receptor ii binding and glycan content